346 related articles for article (PubMed ID: 21910805)
1. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up.
Rossi A; Cantisani C; Scarnò M; Trucchia A; Fortuna MC; Calvieri S
Dermatol Ther; 2011; 24(4):455-61. PubMed ID: 21910805
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
Sato A; Takeda A
J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
Lynn R; Krunic A
Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
[TBL] [Abstract][Full Text] [Related]
4. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
Price VH; Roberts JL; Hordinsky M; Olsen EA; Savin R; Bergfeld W; Fiedler V; Lucky A; Whiting DA; Pappas F; Culbertson J; Kotey P; Meehan A; Waldstreicher J
J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):768-76. PubMed ID: 11050579
[TBL] [Abstract][Full Text] [Related]
5. Oral finasteride improved the quality of life of androgenetic alopecia patients.
Yamazaki M; Miyakura T; Uchiyama M; Hobo A; Irisawa R; Tsuboi R
J Dermatol; 2011 Aug; 38(8):773-7. PubMed ID: 21806672
[TBL] [Abstract][Full Text] [Related]
6. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
Camacho FM; García-Hernández MJ; Fernández-Crehuet JL
Br J Dermatol; 2008 May; 158(5):1121-4. PubMed ID: 18363752
[TBL] [Abstract][Full Text] [Related]
7. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results.
Price VH; Menefee E; Sanchez M; Kaufman KD
J Am Acad Dermatol; 2006 Jul; 55(1):71-4. PubMed ID: 16781295
[TBL] [Abstract][Full Text] [Related]
8. Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia.
Yoshitake T; Takeda A; Ohki K; Inoue Y; Yamawaki T; Otsuka S; Akimoto M; Nemoto M; Shimakura Y; Sato A
J Dermatol; 2015 Jul; 42(7):735-8. PubMed ID: 25903108
[TBL] [Abstract][Full Text] [Related]
9. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.
Shin JW; Chung EH; Kim MB; Kim TO; Kim WI; Huh CH
J Dermatol; 2019 Feb; 46(2):139-143. PubMed ID: 30536893
[TBL] [Abstract][Full Text] [Related]
11. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients.
Moreno-Arrones OM; Becerra A; Vano-Galvan S
Clin Exp Dermatol; 2017 Oct; 42(7):743-748. PubMed ID: 28691187
[TBL] [Abstract][Full Text] [Related]
13. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
14. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
[TBL] [Abstract][Full Text] [Related]
15. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
Rossi A; Mari E; Scarno M; Garelli V; Maxia C; Scali E; Iorio A; Carlesimo M
Int J Immunopathol Pharmacol; 2012; 25(4):1167-73. PubMed ID: 23298508
[TBL] [Abstract][Full Text] [Related]
16. Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study.
Lin JH; Chen WC
Kaohsiung J Med Sci; 2002 Aug; 18(8):379-85. PubMed ID: 12476680
[TBL] [Abstract][Full Text] [Related]
17. Finasteride in the treatment of Japanese men with male pattern hair loss.
Kawashima M; Hayashi N; Igarashi A; Kitahara H; Maeguchi M; Mizuno A; Murata Y; Nogita T; Toda K; Tsuboi R; Ueki R; Yamada M; Yamazaki M; Matsuda T; Natsumeda Y; Takahashi K; Harada S
Eur J Dermatol; 2004; 14(4):247-54. PubMed ID: 15319158
[TBL] [Abstract][Full Text] [Related]
18. Caspase-1 level is higher in the scalp in androgenetic alopecia.
de Rivero Vaccari JP; Sawaya ME; Brand F; Nusbaum BP; Bauman AJ; Bramlett HM; Dietrich WD; Keane RW
Dermatol Surg; 2012 Jul; 38(7 Pt 1):1033-9. PubMed ID: 22404322
[TBL] [Abstract][Full Text] [Related]
19. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Tanglertsampan C
J Med Assoc Thai; 2012 Oct; 95(10):1312-6. PubMed ID: 23193746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
